Skip to main content

Table 1 Clinicopathological data for the fresh frozen and paraffin-embedded MBC tumors, respectively

From: Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies N-acetyltransferase-1 (NAT1) as a novel prognostic biomarker

Clinicopathological characteristics

Fresh frozen tumors N (%)

Paraffin-embedded tumors N (%)

Age at diagnosis

  

   Mean

69

70

   Range

42 to 93

23 to 98

Tumor size

  

   T1

18 (27)

93 (42)

   T2

38 (58)

91 (41)

   N/A

10 (15)

36 (16)

Node status

  

   N0

16 (24)

83 (38)

   N+

37 (56)

78 (35)

   N/A

13 (20)

59 (27)

ER status

  

   Positive

52 (79)

193 (88)

   Negative

3 (5)

9 (4)

   N/A

11 (17)

18 (8)

PR status

  

   Positive

46 (70)

160 (73)

   Negative

9 (14)

41 (19)

   N/A

11 (17)

19 (9)

HER2 status

  

   Positive

2 (3)

18 (8)

   Negative

35 (53)

157 (71)

   N/A

29 (44)

45 (20)

BRCA2 mutation status

  

   Positive

3 (5)

5 (2)

   Negative

7 (11)

12 (5)

   N/A

56 (85)

203 (92)

Histology

  

   DCIS

1 (2)

4 (2)

   Invasive cancer in combination with DCIS

14 (21)

47 (21)

   Invasive cancer

43 (65)

130 (59)

   N/A

8 (12)

39 (18)

NHG

  

   I

2 (3)

15 (7)

   II

17 (26)

98 (44)

   III

19 (29)

85 (39)

   N/A

28 (42)

22 (10)

Metastases

  

   Yes

16 (24)

46 (21)

   No

39 (59)

123 (56)

   N/A

11 (17)

51 (23)

Follow-up time (years)

  

   Mean

5.3

4.6

   Range

0.20 to 15

0.04 to 15

Adjuvant chemotherapy

  

   Yes

6 (9)

21 (10)

   No

51 (77)

159 (72)

   N/A

9 (14)

40 (18)

Adjuvant endocrine therapy

  

   Yes

37 (56)

120 (55)

   No

20 (30)

66 (30)

   N/A

9 (14)

34 (15)

Post-operative radiotherapy

  

   Yes

30 (45)

85 (39)

   No

28 (42)

96 (44)

   N/A

8 (12)

39 (18)

Surgery

  

   Mastectomy

58 (88)

178 (81)

   Lumpectomy

1 (2)

12 (5)

   No surgery

0 (0)

2 (1)

   N/A

7 (11)

28 (13)